COMMUNIQUÉS West-GlobeNewswire

IBA – Share buyback
02/02/2026
Louvain-la-Neuve, Belgium, February 2 nd , 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, [...]
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
02/02/2026
Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 2 February 2026, 6 : 00 pm CET Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) ( [...]
EssilorLuxottica: Full-Year 2025 Results Conference Call Invitation
02/02/2026
Full-Year 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
KabaFusion and Nautic Partners Announce Completion of Significant Growth Investment
02/02/2026
LEXINGTON, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- KabaFusion (the “Company”), a nationally recognized leader in home and alternative site infusion, and Nautic Partners (“Nautic”) announced today that Nautic has [...]
IBA – Rachat d’Actions Propres
02/02/2026
Louvain-la-Neuve, Belgique, 2 février 2026 – 18h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules, annonce aujourd’hui le lancement d’un programme de rachat d’ [...]
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
02/02/2026
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss 1 . CagriSema achieved superior HbA 1c reduction of up to 1.91%- [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
CorMedix Therapeutics Announces Share Repurchase Program
02/02/2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
02/02/2026
ORLANDO, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (“SDL”), a Florida-based dental laboratory platform focused on high-quality clinical outcomes and long-term practitioner relationships, today [...]
Iridex Announces Plans to Relocate Headquarters
02/02/2026
Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
02/02/2026
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the [...]
Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence
02/02/2026
Reinforcing AbinoNutra® NMN as a clinically validated, science-driven ingredient for NAD⁺ support and healthy longevity SHELTON, Conn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Abinopharm, Inc. , a U.S.-based life-science [...]
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address [...]
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
02/02/2026
XanaMIA trial fully enrolled with final results expected in November 2026 SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’ [...]
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
02/02/2026
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding [...]
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today [...]
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
02/02/2026
For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a [...]
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
02/02/2026
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile [...]

Pages